来源: Pharmaceutical Technology
Allakos is halting all lirentelimab-related activities and axing half of its workforce. Credit: Pavel Kapysh via Shutterstock. Free ReportHow is the Biopharmaceutical industry evolving?
2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.
Benchmark the impact of major themes on the Biopharmaceutical industry.
Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success.
来源: Pharmaceutical Technology
Antigua & Barbuda (+1268)
Bosnia Herzegovina (+387)
Cape Verde Islands (+238)
Central African Republic (+236)
Dominican Republic (+1809)
Sao Tome & Principe (+239)
Trinidad & Tobago (+1868)
Turks & Caicos Islands (+1649)
United Arab Emirates (+971)
Virgin Islands - British (+1284)
Virgin Islands - US (+1340)
Bonaire, Sint Eustatius and Saba
British Indian Ocean Territory
French Southern Territories
Heard Island and McDonald Islands
Saint Helena, Ascension and Tristan da Cunha
Saint Pierre and Miquelon
Saint Vincent and The Grenadines
South Georgia and The South
US Minor Outlying Islands
-->By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Submit
Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Thank you.You will recieve your mail in sometime.So, please check your email to download the Report.
Go deeper with GlobalData
来源: Pharmaceutical Technology
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Alpelisib in Mutational Disorders The gold standard of business intelligence.
Related Company ProfilesAllakos IncView all
In the Phase II ATLAS trial (NCT05155085) assessing lirentelimab for patients with atopic dermatitis, the primary endpoint – measuring the proportion of patients achieving a 75% reduction from baseline in Eczema Area and Severity Index (EASI-75) – did not achieve statistical significance, with 23% of patients treated with lirentelimab achieving EASI-75 compared to 18% of patients in the placebo group. The primary endpoint also fell short in the Phase IIb MAVERICK trial (NCT05528861) assessing patients with chronic spontaneous urticaria, with those in the lirentelimab group experiencing a change of -27% in urticaria activity score (UAS7), compared to a change of -26% in the placebo group. In response to these results, Allakos said it is initiating a workforce reduction of approximately 50% to reduce costs and ensure an extended cash runway. Additionally, the company will now also halt all lirentilimab-related activities. Allakos’ stock has plunged 59% after announcing the results on 16 January, compared to the price on the previous trading day of 12 January. Allakos will now concentrate its efforts on AK006, a humanised IgG1 monoclonal antibody candidate. An ongoing Phase I study for AK006 in healthy volunteers is set to progress, with the completion of its single and multiple ascending dose cohorts expected by Q1 2024. While lirentelimab targeted Siglec-8, which is found on mast cells and eosinophils, AK002 is an agonist of Siglec-6, which is exclusively expressed on mature mast cells. Mast cells and eosinophils are types of immune cells, and are studied to understand a drug’s activity. In the ATLAS study, blood eosinophil counts of lirentelimab-treated patients decreased by 96% compared to 15% for those on placebo. The San Carlos, California-headquartered company plans to launch a Phase I trial for intravenous AK006 in chronic spontaneous urticaria in Q2 2024, anticipating topline data by the end of the year. In the announcement accompanying the results, chief medical officer of Allakos Craig Paterson said: “We are disappointed that these trials did not meet their primary endpoint, particularly given the need for new treatment options for patients with these severe diseases. Given that neither trial met its primary endpoint, we have decided to not pursue further clinical development of lirentelimab.” Free ReportHow is the Biopharmaceutical industry evolving?
2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.
Benchmark the impact of major themes on the Biopharmaceutical industry.
Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success.
来源: Pharmaceutical Technology
Antigua & Barbuda (+1268)
Bosnia Herzegovina (+387)
Cape Verde Islands (+238)
Central African Republic (+236)
Dominican Republic (+1809)
Sao Tome & Principe (+239)
Trinidad & Tobago (+1868)
Turks & Caicos Islands (+1649)
United Arab Emirates (+971)
Virgin Islands - British (+1284)
Virgin Islands - US (+1340)
Bonaire, Sint Eustatius and Saba
British Indian Ocean Territory
French Southern Territories
Heard Island and McDonald Islands
Saint Helena, Ascension and Tristan da Cunha
Saint Pierre and Miquelon
Saint Vincent and The Grenadines
South Georgia and The South
US Minor Outlying Islands
-->By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Submit
Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Thank you.You will recieve your mail in sometime.So, please check your email to download the Report.